

BAL PHARMA LIMITED
Regd. Office: 21-22 Bommasandra Industrial Area, Anekal Taluq, Bangalore 560 099
UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30.06.2014
CIN # : L85110KA1987PLC008368, URL : www.balpharma.com, email ID : secretarial@balpharma.com

(` in Lakhs)

Sr. No:	Particulars	Quarter Ended			
		30.06.2014	31.03.2014	30.06.2013	31.03.2014
		Unaudited			Audited
Part-I					
1	Net Sales/Income from operations (Net of Excise Duty)	4,144.60	4,662.07	3,676.16	17,341.40
	Other Operating Income	89.43	245.14	94.05	545.80
	Net Income from Sales/Services	4,234.03	4,907.21	3,770.21	17,887.20
2	Expenditure				
	a) Increase/decrease in stock in trade and WIP	(192.75)	107.07	(58.88)	95.94
	b) Consumption of Raw Materials/ Packing Material	2,264.55	2,435.20	1,778.68	8,911.84
	c) Purchase of Stock in Trade	106.50	144.04	74.57	515.41
	d) Employee Cost	764.33	744.86	655.30	2,812.36
	e) Depreciation and amortisation expenses	112.14	101.72	152.26	473.97
	f) Other Expenditure	890.95	1,035.27	877.96	3,763.97
	g) Total	3,945.72	4,568.16	3,479.89	16,573.49
3	Profit from Operations before other Income, interest and Exceptional items(1-2)	288.31	339.05	290.32	1,313.71
4	Other Non-operating Income	6.03	37.20	7.90	64.63
5	Profit before Interest and Exceptional items (3+4)	294.34	376.25	298.22	1,378.34
6	Finance Costs	162.73	181.85	181.99	715.74
7	Profit after Interest but before Exceptional items	131.61	194.40	116.23	662.60
8	Exceptional items	-	-	-	-
9	Profit/Loss from ordinary activities Before Tax (7-8)	131.61	194.40	116.23	662.60
10	Tax expenses	33.20	58.63	24.78	155.37
11	Net Profit /Loss from ordinary Activities after Tax	98.41	135.77	91.45	507.23
12	Extra ordinary items	-	-	-	-
13	Net Profit / Loss for the period	98.41	135.77	91.45	507.23
14	Paid-up Equity Share capital(face value of Rs 10 each)	1,287.24	1,111.14	1,057.36	1,111.14
15	Reserves excluding Revaluation Reserves as per balance sheet of previous accounting year				3,283.79
16	EPS (in Rs.)				
	a) Basic	0.78	1.25	0.86	4.77
	b) Diluted	0.78	1.21	0.86	4.60
Part II					
Particulars of Share Holding					
17	Public shareholding				
	- Number of Shares	6,586,570	5,142,086	5,142,086	5,142,086
	- Percentage of shareholding	51.17	46.28	48.63	46.28
18	Promoters & Promoter group Shareholding				
	a) Pledged / Encumbered				
	- Number of Shares	-	-	-	-
	- Percentage of shareholding	-	-	-	-
	b) Non-encumbered				
	- Number of Shares	6,285,802	5,969,302	5,431,538	5,969,302
	- Percentage of shareholding	48.83	53.72	51.37	53.72

Notes:

- The above Un-audited financials results as reviewed by the Audit Committee were approved by the Board of Directors at its meeting held on 11.08.2014
- Statutory Auditors have conducted limited review on the Un-Audited financial results for the quarter ended 30.06.2014.
- Investor grievances : Outstanding at the beginning of the quarter : Nil, received during the quarter : 2, resolved during the quarter 2: pending at the end of the quarter : Nil.
- With reference to the Limited Review Report Dated 11.08.2014 by statutory Auditors on Depreciation provision : With effect from 1st April 2014, Companies Act, 2013 prescribes for the useful lives of various assets. Pending determination of various useful lives of assets, the Company continues to provide depreciation at the rates prescribed hitherto.
- Previous year figures were regrouped/rearranged to conform to the classification of current year.
- As the Company deals with single product i.e pharmaceuticals, segment wise figures are not furnished.

Bangalore
11.08.2014

By order of the Board of Directors
For Bal Pharma limited

Shailesh Siroya
Managing Director